Crescent Grove Advisors’s Oncolytics Biotech ONCY Stock Holding History

Crescent Grove Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$21K	–	303
2021 Q3	$21K	Hold	10,000	–	–	﹤0.01%	268
2021 Q2	$28K	Hold	10,000	–	–	﹤0.01%	262
2021 Q1	$38K	Hold	10,000	–	–	﹤0.01%	210
2020 Q4	$24K	Hold	10,000	–	–	﹤0.01%	183
2020 Q3	$17K	Hold	10,000	–	–	﹤0.01%	169
2020 Q2	$19K	Sell	10,000 -790	-7%	-$1.49K	﹤0.01%	151
2020 Q1	$15K	Hold	10,790	–	–	﹤0.01%	144
2019 Q4	$51K	Buy	+10,790	New	+$12.2K	0.01%	156

Other funds holding ONCY

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crescent Grove Advisors's ONCY Position: Q4 2021 in Review

Crescent Grove Advisors sold out of Oncolytics Biotech (ONCY) in Q4 2021, closing a stake of 10,000 shares — an estimated $21K sold.

Crescent Grove Advisors first reported a position in ONCY in Q4 2019 and held it in 8 quarters. The position peaked at $51K in Q4 2019. 45 funds tracked by Wall St. Rank hold ONCY as of Q4 2021.

Crescent Grove Advisors reported no remaining Oncolytics Biotech position as of Q4 2021 after selling out during the quarter.
Crescent Grove Advisors sold 10,000 Oncolytics Biotech shares in Q4 2021, an estimated $21K.
Crescent Grove Advisors first reported a position in Oncolytics Biotech in Q4 2019 and held it in 8 quarters.
Crescent Grove Advisors's Oncolytics Biotech position peaked at $51K in Q4 2019.
45 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2021.

Based on Crescent Grove Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.